Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Dawson James Downgrades BioCardia to Neutral

Dawson James Downgrades BioCardia to Neutral

Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.

byBenzinga Newsdesk

November 11, 2022

1 minute read

Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.

BMO Capital Maintains Outperform on Phathom Pharmaceuticals, Lowers Price Target to $30

By Benzinga Newsdesk

March 1, 8:39 AM

BMO Capital analyst Gary Nachman maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Outperform and lowers the price target from $35 to $30.

PHAT

Atari Acquires Intellivision: Ending Decades-Long Gaming Rivalry

By Franca Quarneti

May 24, 1:38 PM

Atari acquires Intellivision, ending a historic rivalry and expanding its game library. The Intellivision Amico console is not included.

MAT

TAL Education Q3 Adj EPS $(0.04) Misses $0.02 Estimate, Sales $232.70M Miss $239.83M Estimate

By Benzinga Newsdesk

January 19, 5:07 AM

TAL Education (NYSE:TAL) reported adjusted quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.02 by 300 percent. This is a 55.56 percent increase over losses of $(0.09) per share from

TAL

What Does Apple’s Debt Look Like?

By Benzinga Insights

April 18, 9:30 AM

Shares of Apple Inc. (NASDAQ:AAPL) increased by 20.58% in the past three months. Before having a look at…

AAPL

Dawson James Downgrades BioCardia to Neutral

Related Posts

BMO Capital Maintains Outperform on Phathom Pharmaceuticals, Lowers Price Target to $30

Atari Acquires Intellivision: Ending Decades-Long Gaming Rivalry

TAL Education Q3 Adj EPS $(0.04) Misses $0.02 Estimate, Sales $232.70M Miss $239.83M Estimate

What Does Apple’s Debt Look Like?